profit from every $100 of sales.
$0$100
Vera Therapeutics
$30.48+1.50% today
+2.6% in 1 year
1-year low $26.741-year high $55.67
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Vera Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$300 million of profit last year.
SalesProfit
Vera Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vera Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Vera Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -91 | -102 | -167 | -315 | |
| -88 | -92 | -144 | -292 | |
| -89 | -96 | -152 | -300 | |
| -3.35 | -2.25 | -2.75 | -4.66 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 131 | 176 | 656 | 735 |
| Cash | 43 | 46 | 93 | 355 |
| Total debt | 31 | 54 | 55 | 77 |
| Total liabilities | 55 | 74 | 79 | 130 |
| 77 | 102 | 577 | 605 | |
| 27 | 43 | 55 | 64 | |
| -64.3% | -46.9% | -18.1% | -33.8% | |
| -115.8% | -94.4% | -26.4% | -49.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -68 | -92 | -135 | -241 | |
| 0 | 0 | 1 | 1 | |
| -68 | -92 | -136 | -242 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 9 | 11 | 21 | 38 |
Valuation
- –
- –
- –
- 5.4×
- –
- –
- –
- -11.0%
- -13.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -66.5%
- -51.2%
- -74.9%
- -59.3%
- -66.5%
- –
Growth
- –
- –
- −78.2%
- –
- +47.9%
Financial health
- 0.1×
- 0.15
- 12.1%
- -34.0×
- 13.64
- 13.64
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 958
Bottom 21%of 888
Bottom 9%of 987
What analysts expect
- Average price target
- $77.60
- Range
- $33.00 – $97.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.69 | -1.33 | −27.2% |
| Feb 26, 2026 | -1.39 | -1.34 | −3.7% |
| Nov 5, 2025 | -1.26 | -1.20 | −5.0% |
| Aug 5, 2025 | -1.20 | -0.82 | −46.3% |
| May 6, 2025 | -0.81 | -0.75 | −8.0% |
| Feb 26, 2025 | -0.72 | -0.83 | +13.3% |
| Nov 7, 2024 | -0.85 | -0.69 | −23.2% |
| Aug 8, 2024 | -0.62 | -0.58 | −6.9% |
News
Jensen Huang Says Nvidia's Next-Gen Vera Rubin Chips Will Generate $40 Billion in Revenue per Gigawatt, Up From $25 Billion for Grace Blackwell. What That Means for Nvidia's Growth Runway?Yahoo Finance · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
39No pass
Philip Fisher
32No pass
Peter Lynch
57No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Vera Therapeutics
Is Vera Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vera Therapeutics AI analysis
What does Vera Therapeutics do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. It is in Biotechnology, based in Brisbane, CA, United States, with 339 employees.
Does Vera Therapeutics pay a dividend?
No. Vera Therapeutics does not pay a dividend at the moment.
Is Vera Therapeutics stock halal?
Questionable. Vera Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Vera Therapeutics stock done over the past year?
Up 2.6% over the past twelve months, to $30.48. It traded between $26.74 and $55.67 and is 45.2% below its high.
Who are Vera Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Vera Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.